Case study · Signal Intelligence · 17 September 2026
In vivo CAR-T: the regulatory bottleneck moved, in public, three times in six weeks.
Between 9 August and 16 September 2026, the US FDA cleared at least three IND applications for in vivo CAR-T therapies backed by trials run outside the United States, in cohorts as small as eleven patients. Each was reported as one company’s milestone. Read as one pattern, they change the timetable for the whole modality.
Download the full 14-page reportWhat each public layer showed
A named, multi-sponsor clinical pipeline built in under 24 months, with most early human data generated in China and Australia.
Six deals by five large acquirers since March 2025, up to $14.4bn including milestones. They bought delivery platforms, not single molecules.
Four FDA IND clearances in 2026, three inside six weeks, some accepting offshore early data as the basis for advanced US trial entry.
The weakest layer: key delivery claims are still pending. Freedom to operate is unresolved in exactly what buyers paid for.
Confidence: medium-high on the pattern, low on its cause. The FDA publishes no rationale for IND clearances; the report sets out what would prove the reading wrong.
The counter-evidence is in the report too
The first published oncology dataset (five patients) showed grade 3+ adverse events in every patient and one death. The autoimmune dataset (sixteen patients) was much milder. About forty patients have been dosed across all published cohorts: anyone calling this modality de-risked is overselling it.
Six forecasts, dated and scoreable
Each forecast will be marked right or wrong on its date, on our track-record page.
| # | Forecast | Resolves by | Confidence |
|---|---|---|---|
| F1 | At least two further FDA IND clearances for in vivo CAR-T assets whose main evidence is a non-US investigator-initiated trial | 2027-03-31 | 70% |
| F2 | At least one in vivo CAR-T programme placed on FDA clinical hold, or suspended for safety | 2027-12-31 | 55% |
| F3 | No in vivo CAR-T therapy receives FDA marketing approval | 2028-12-31 | 85% |
| F4 | The next three large-cap entries into the field are licensing deals or collaborations, not acquisitions | 2027-12-31 | 60% |
| F5 | A randomised or controlled in vivo CAR-T trial in an autoimmune indication begins enrolling | 2027-12-31 | 50% |
| F6 | Cumulative disclosed in vivo cell-therapy deal value exceeds $18bn | 2027-12-31 | 45% |
The full report
Fourteen pages: every claim with its reliability code and source, the four signal layers, the NCT worked example, counter-signals, forecasts and open questions.
Download the full report (PDF, 14 pages)
The full report is in English.
Want the same analysis on your own indication? Request a free specimen